Skip to main content
Pablo  Menéndez

Pablo Menéndez

Institut de Recerca contra la Leucèmia Josep Carreras

Life & Medical Sciences

Born in Avilés, Asturias, in 1974. Biochemist by University of Salamanca (1997) and PhD in Medicine (Hematology) by the same University in 2002, under the supervision of Prof. Alberto Orfao and Prof. Jesus San Miguel. Postdoctoral training in stem cell biology (Mick Bhatia Laboratory, London, ON, Canada; 2002-2005) and in childhood leukemia (Mel Greaves Laboratory, London, UK; 2005-2007). In 2007, I was appointed Director of the Andalusian Stem Cell Bank, and was leading my own lab at CIBM (Granada, Spain) until July 2011 when I moved to GENyO (Granada, Spain) as Principal Invesigator. In June 2013 I was appointed ICREA Research Professor and Research Director of The Josep Carreras Leukemia Research Institute-Campus Clínic, Barcelona, Spain.

Research interests

1.-Understanding the pathogenesis and cellular origin of MLL-rearranged and MLL-germline Acute Lymphoblastic Leukemia in children.

2.-Leukemic cell-bone marrow environment interactions and targeted therapies in Acute Myeloid Leukemia and therapy resistance.

3.- Adoptive T-cell-based CAR immunotherapy for B-cell, T-cell ALL, AML and bone sarcomas.

4.-Deciphering the intrinsic determinants and signaling pathways underlying hematopoietic from human pluripotent stem cells.


Selected publications

– Manzano A et al 2021, MCL1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-ALL. Front Cell Dev Biol 9:695225

– Bataller A et al 2021 KMT2A-CBL rearrangements in acute leukemias: clinical characteristics and genetic breakpoints, Blood Adv.2021; 5:5617-5620

– L Godfrey et al 2021, ‘H3K79me2/3 controls enhancer promoter interactions and activation of PROM1 in MLLAF4 leukemia cells’. Leukemia, 35(1):90-106.

– Jaffredo T et al 2021, The EHA Research Roadmap: Normal Hematopoiesis’, Hemasphere 5:12,e669.

– Barrios et al 2021, HDAC7 is a major contributor in the pathogenesis of infant t(4;11) proB ALL. Leukemia 35:2086-91.

– O Molina et al 2021 Near-haploidy and low-hypodiploidy in B-cell ALL: when less is too much. Cancers 14,32.

– Sanchez et al 2021, Enforced sialyl-Lewis-X in E-selectin ligands by exofucosylation is dispensable for CD19CAR T activity and BM homing. Clin Transl Med. 11:e280.

– Molina O et al 2021, Aneuploidy in Cancer: Lessons from ALL, Trends Cancer, (1):37-47.

– R Díaz  Guardia et al 2021, ‘Characterization of the engraftment of risk-stratified AML patients in NSGS mice’. Blood Adv 5(23):4842-4854.

– Gutiérrez et al 2021, A benchmarking comparison of protocols for hematopoietic differentiation from hPSC. Front Cell Dev Biol,9:636704.

– J Tejedor et al 2021. Integrative methylome-transcriptome analysis unravels cancer-cell vulnerabilities in infant MLL B-ALL. J Clin Invest, 13:e138833.

– J García-Castillo et al 2021, Telomerase RNA recruits RNA polymerase II to target gene promoters to enhance myelopoiesis. Proc Natl Acad Sci USA.;118(32):e2015528118.

– M Ribeiro et al, ‘ Antitumoral activity of the novel BTK inhibitor TG-1701 is associated with disruption of Ikaros signaling in B-cell non-Hodgkin lymphoma‘. CCR, 27,6591-601.

Selected research activities

– Designation of Orphan Drug – European Medicines Agency. CD1aCARTs for relapsed CD1a+ TALL. EMA/OD/0000062804 November 5th

– Chief Scientific Officer OneChain Immunotherapeutics Sl

ICREA Memoir 2021